תבנית:תרופה/קפרה 250 מ"ג - Keppra 250 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | N03AX Other antiepileptics |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | פ××× - PER OS |
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | - Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. - Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - Keppra is indicated as adjunctive therapy in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/×§×¤×¨× 250 ×"× - Keppra 250 mg | |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ×§×¤×¨× 250 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | UCB PHARMA S.A., BELGIUM |
| ×©× ××¢× ×ר×ש×× | CTS LTD |
| ר×ש××× | ת×ר×× ××ש×: 12/2004. ר×ש××× ×ת×ר××: 02/2015 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
ת××× ×ª ×ר×××
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: ×§×¤×¨× 250 ×"× - Keppra 250 mg
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/×§×¤×¨× 250 ×"× - Keppra 250 mg}}
×:
{{תר×פ×/×§×¤×¨× 250 ×"× - Keppra 250 mg
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־7 באפריל 2023 ב־16:06